Follow the 지노믹트리 stock price and the full management transaction log of the company, a listed equity based in South Korea. Shares trade on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 지노믹트리 has logged 27 reports. The latest transaction was reported on 22 May 2026 (Purchase). Among the most active insiders: 이홍선. All data is accessible without an account.
27
Insider Decl.
n/a
Thresholds
n/a
19 ops.
Buy Volume
n/a
6 ops.
Sell Volume
11Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Genomictree is a leader in genetic testing in South Korea, providing innovative solutions for the diagnosis and treatment of diseases. The company is listed on the XKRX market.